Jocasta Neuroscience is a pre-clinical stage biotech company focused on developing a proprietary formulation of a-Klotho protein (JN-0413) to manage cognitive decline associated with various forms of neurodegenerative-induced dementia. Jocasta's foundational data demonstrates the critical role of a-Klotho in health and disease. Results ranging from human genetics (effect of KL mutations in humans) to robust cognitive enhancement in healthy rats, rodent disease models and non-human primates strongly support the advancement of JN-0413 into clinical trials in patients with dementia and cognitive decline.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/12/25 | $35,000,000 | Series A |
Glentura Moore Strategic Ventures SC8 Investments True Ventures  Yagan Family Foundation | undisclosed |
